Bexar Biomedical, LLC

Company Contact:

Legal Entity Type: LLC

Company Type: Medical Device

Company Stage: Development

No. of Employees: 5

Desired Financial Amount: $276,000


Company Background

Bexar Biomedical offers combined technology from MA (Paul Fenton, Ralph Johnston, Jeff Johnston) and UTSA (Doug Frantz, Lyle Hood). We are developing a mini-Intrathecal drug delivery system (pump and catheter, “MiniFuse”) to provide central nervous system (CNS) access for drugs across the blood: brain barrier. Implantable pumps have been on the market since the early 1980’s from Infusaid Corporation, later Pfizer Infusaid, Medtronic and Flowonics. Infusaid pioneered the first pump that was mechanical, gas-powered (freon), non-electric, and externally refillable, (50ml) initially indicated to treat metastatic liver cancer. Subsequently, the pumps were applied to pain management for cancer, chronic pain syndromes, and spasticity. Bexar Biomedical is advancing the state of the art with a smaller 15ml mini-pump to reduce size, cost, and improve compatibility with newer drugs. Our team is comprised of engineers, medicinal chemist, and marketeers.


R. Lyle Hood, PhD Biomedical Engineer Doug Frantz, PhD Medicinal Chemist Paul Fenton, BBA Designer Ralph Johnston, MBA Business Development Jeff Johnston, BS Finance

Board of directors

R. Lyle Hood, PhD Biomedical Engineer Doug Frantz, PhD Medicinal Chemist Paul Fenton, BBA Designer Ralph Johnston, MBA

Product / Service

disease area / application

Cancer and chronic pain, spasticity

product / Service

Treatment of chronic pain patients with cancer and back pain is often accomplished by intrathecal (subarachnoid) infusion. Intrathecal infusion is a proven route for pain medication delivery that provides pain relief with a minimal amount of medication and reduced side effects. Novel non-opioid medications are being developed for this field and Bexar Biomedical plans to provide a cost-effective intrathecal implant for delivery of new and existing drugs.

technology / ip

The Bexar Biomedical MiniFuse will provide a smaller, completely composite design and with a novel radio frequency (RF) low voltage antenna that will provide non-electronic external interrogation of the MiniFuse without a battery. These novel enhancements will benefit all aqueous drugs delivered. Currently Bexar Biomedical has received two patents licensed from UTSA and Fenton, Johnston, two patents are pending and additional IP is planned.

distribution channels

Direct/Distributor Sales channels

market size

In 2016, an estimated 20.4% of U.S. adults had chronic pain and 8.0% of U.S. adults had high-impact chronic pain. $50 billion was spent in the US for treating back pain. The chronic back pain market is estimated to be $9.2 billion annually growing at 5.2% per annum


Primary competitors include Medtronic and a new entrant, Nevro. Both Medtronic and Nevro use spinal cord stimulation which requires either a battery or external recharging. Medtronic can also use intrathecal drug delivery (morphine, Prialt) via a pump but this requires a battery, has 2-3 year shelf life and their pump must be explanted and replaced. Only Bexar Biomedical will utilize its novel and patent protected MiniFuse pump with a low voltage antenna to provide power.


Desired financial amount


previous funding

Pending NSG grant.

current financials

Bexar is pre-clinical and pursuing our initial financing.

financial use

Feasibility and initial design concepts.


Direct salse

exit strategy

We intend to build the company in San Antonio as it will serve a number of drugs that must past the blood: brain barrier for other chronic diseases.


Welcome back! Login below